• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Kuwait Pharmaceuticals and Healthcare Report Q1 2009 Product Image

Kuwait Pharmaceuticals and Healthcare Report Q1 2009

  • Published: February 2009
  • Region: World
  • 75 Pages
  • Business Monitor International

FEATURED COMPANIES

  • Bader Sultan & Bros
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co
  • Novartis
  • Pfizer
  • MORE

We are forecasting that a worsening economic environment in Kuwait, caused by falling oil prices, will negatively impact the pharmaceutical market, which by 2013 will slip into negative growth. In the short term, however, growth in nominal terms will be high, driven by a rapidly expanding population and growing health awareness, even if high inflation levels will erode these gains somewhat. In nominal terms the market should expand at a compound annual growth rate (CAGR) of 5.15% between 2008-2013, reaching a total value of US$502.4mn.

Meanwhile, there are reports that emergency departments at government hospitals in Kuwait face a shortage of doctors. An excessive work load and lack of emergency allowances are primarily responsible for this situation. The pressure in the emergency departments increases substantially during evenings in Ramadan, when admissions tend to increase. Commentators claim that there needs to be more awareness campaigns to educate people to control the rush at emergency departments, as approximately 50% of cases dealt with by these departments can be dealt with by primary health centres.

Meanwhile, continuing the trend for Bangladeshi drugmakers READ MORE >

Executive Summary
Kuwait Pharmaceuticals And Healthcare Industry SWOT
Kuwait Political SWOT
Kuwait Economic SWOT
Kuwait Business Environment SWOT
Pharmaceutical Business Environment Rating
Table: Kuwait Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
Kuwait – Market Summary
Regulatory Regime
Foreign Direct Investment Regulations
Intellectual Property Regime
IP Shortcomings
Pricing And Reimbursement Regime
Public Procurement Of Medicines
Regional Harmonisation
Free Trade Agreements
Industry Developments
Epidemiology
Recent Public Health Developments
Healthcare Sector
Primary Care
Secondary Care
Recent Healthcare Sector Developments
Healthcare Insurance
Healthcare Reforms
Regional Developments
International Collaboration
Pharmaceutical Sector
Research And Development
Biotechnology Sector
Medical Devices
Industry Forecast Scenario
Overall Market Forecasts
Table: Drug Expenditure And Prescription Market Indicators, 2004-2013 (KWDmn unless otherwise stated)
Key Growth Factors – Industry
Table: Kuwait’s Health Expenditure, 2004-2013 37
Key Growth Factors – Macroeconomic
Table: Kuwait – Economic Activity
Patented Drug Market Forecast
Table: Kuwait’s Generics And Patented Market Indicators, 2004-2013
Generics Market Forecast
Table: Kuwait’s Generics Market Indicators, 2004-2013
OTC Market Forecast
Table: Kuwait’s OTC Market, 2004-2013 (KWDmn unless otherwise stated) 48
Export/Import Market Forecasts
Table: Kuwait’s Pharmaceutical Trade Indicators, 2004-2013 (US$mn unless otherwise stated)
Table: India’s Export Of Pharmaceutical Products To The GCC Countries (US$mn)
Other Healthcare Data
Table: Kuwait – Other Healthcare Indicators, 2004-2013
Key Risks To BMI Forecasts
Competitive Landscape
Company Profiles
Multinationals
Novartis
Sanofi-Aventis
Pfizer
GlaxoSmithKline
Merck & Co
Johnson & Johnson
Indigenous Players
Advanced Technology Company
Bader Sultan & Bros
Safwan Trading And Contracting Company
Country Snapshot: Kuwait Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 1997-2006
Table: Consumer Expenditure, 2000-2012
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources

-Novartis
-Sanofi-Aventis
-Pfizer
-GlaxoSmithKline
-Merck & Co
-Johnson & Johnson
-Advanced Technology Company
-Bader Sultan & Bros
-Safwan Trading And Contracting Company

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos